We are pleased to announce that Optieum Biotechnologies Inc. has entered into a research collaboration with Daiichi Sankyo Company, Limited. (Tokyo: 4568). Optieum Biotechnologies intends to use its Eumbody System technology to identify a new functional single chain fragment variables (scFvs) that can be utilized for CAR-T cell against the target of interest selected by Daiichi Sankyo.

　Eumbody System is a single-chain antibody generation system yielding CAR-T cells with superior antitumor function developed by Dr. Toshiki Ochi, co-founder of Optieum Biotechnologies, which exclusive license is granted to Optieum Biotechnologies.

　Under the terms of the agreement, Optieum Biotechnologies will receive an undisclosed upfront payment, and is eligible for payments associated with the achievement of certain development milestones.

http://optieumbio.com/wp-content/uploads/2021/03/20210319_Announcement-of-Research-Collaboration-with-Daiichi-Sankyo.pdf